Assembling evidence grade
Loading
Independent evidence before payment.
GHRH analogue · also: TH9507, Egrifta
Tesamorelin carries an Evidence Grade of A (High confidence). The strongest published evidence catalogued is human rct / review.
Grade A rule: Two or more confirmatory human RCTs (an approved product, or completed Phase 3).
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Tesamorelin is a GHRH analogue with randomised human evidence in HIV-associated lipodystrophy, where a branded formulation is approved.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 2 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024.
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine, 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Tesamorelin. PubMed, 2018.
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 2012.
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011.
Tesamorelin. Nature reviews. Drug discovery, 2011.
Tesamorelin update. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2010.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Approved evidence concerns a specific population and branded product. It does not transfer to general use or unbranded material.
An approved prescription-only medicine. Buying it without a prescription bypasses medical supervision and the approved supply chain — a vendor selling it as “research use only” is offering a prescription drug with no prescription and no clinical oversight.
PepCred flags any vendor selling this compound without requiring a prescription as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
The molecule is FDA-approved (US) as a branded medicine (Egrifta SV, Egrifta WR). The unbranded, research-grade material sold as Tesamorelin is a different, unapproved product of unverified identity, purity and concentration.
Reporting volume (not a safety rate): 1,586 adverse-event reports name this ingredient in the FDA FAERS database. FAERS reports are voluntary and unverified, are not a rate, and do not establish that the drug caused the event — high counts usually track high prescribing volume.
PepCred note: Approved branded formulation for a specific indication (FDA).
Tesamorelin is a prescription-only medicine. The lawful route is a prescriber and a GPhC-registered pharmacy — never a grey-market seller.
Get Tesamorelin only through a prescriber and a GPhC-registered pharmacy. The registered pharmacies in the PepCred directory are UK weight-management (GLP-1) services and may not dispense Tesamorelin — ask a pharmacy or your GP, and check any pharmacy against the official register before you buy.
An ingredient-name listing is not the licensed branded medicine. These unranked records are shown to expose prescription bypass and other risks, not to suggest where to buy.
None of these is verified for human use.